Skip to content

To study the effect of ayurvedic formulation in hyper lipidima

Randomized controlled clinical study to evaluate an adjuvant effect of Trayushnadyam churna with diet and exercise in Medoroga with special reference of dyslipidemia.

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/08/072604
Enrollment
80
Registered
2024-08-16
Start date
Unknown
Completion date
Unknown
Last updated
2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E784- Other hyperlipidemia

Interventions

None listed

Sponsors

Dr Shraddha Shankar Wavare
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients of age group 21-60 irrespective of their gende2.Patients of medoroga as per signs and symptoms mention in Ayurvedic samhita and hyperlipidemia condition.3. the patient who has in between values of either 1. serum cholesterol 200-240 mg dl or 2.serum triglycerides 150-400 mg dl

Exclusion criteria

Exclusion criteria: 1.Pregnant women or lactating mother 2. Acute life threatening conditions like cancer and post MI 3. Obesity due to other conditions like endocrinal diseases 4. Patients diagnosed with diabetes mellitus type 2, immunological diseases and hypertension.

Design outcomes

Primary

MeasureTime frame
To decrease the kshudrashwas, Daurbalya,Sarvkriya Asamartha, Alpapran,Atinidra,Kshudha atiyoga,Pipasa atiyog mentioned in ayurvedaTimepoint: 90 days study with follow up on 30th,60th,90th day

Secondary

MeasureTime frame
To study the effect on1Serum Cholesterol 2.Serum Triglyceride 3.HDL 4.LDL in MedorogaTimepoint: 90 days study with follow up on 30th, 60th, 90th day (0,30,60,90)

Countries

India

Contacts

Public ContactDr Shraddha Shankar Wavare

Loknete Rajaram bapu Patil Ayurvedic Mahavidyalaya

amitchingale257@gmail.com7350420508

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026